<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html >
<head>
<title>Office of Generic Drugs Home Page</title>
<meta http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<meta http-equiv=Content-language content=en>
<meta name=description content="Office of Generic Drugs Home Page">
<meta name=posted content="06-03-2002">
<meta name=poster content="Dawn Arculus">
<meta name=updated content="2008-12-18">
<meta name="AUTHOR" content="AMEST">
<title>Office of Generic Drugs Home Page</title>
<style type=text/css>
BODY {MARGIN-TOP: 2%; MARGIN-LEFT: 2%; COLOR: #000000; MARGIN-RIGHT: 2%; BACKGROUND-COLOR: #336699; FONT-FAMILY: Arial, Helvetica, sans-serif}
.header {MARGIN-TOP: 9px; FONT-SIZE: 0.7em; MARGIN-BOTTOM: 11px; COLOR: #000000; FONT-FAMILY: Arial, Helvetica, sans-serif; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: center}
.header2 {MARGIN-TOP: 2px; FONT-WEIGHT: bold; FONT-SIZE: 1em; MARGIN-BOTTOM: 3px; COLOR: #000000; FONT-FAMILY: Arial, Helvetica, sans-serif; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: center}
.header3 {MARGIN-TOP: 2px; FONT-WEIGHT: bold; FONT-SIZE: 1.5em; MARGIN-BOTTOM: 3px; COLOR: #000000; FONT-FAMILY: Arial, Helvetica, sans-serif; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: center}
.header4 {MARGIN-TOP: 2px; FONT-WEIGHT: bold; FONT-SIZE: 1.25em; MARGIN-BOTTOM: 3px; COLOR: #000000; FONT-FAMILY: Arial, Helvetica, sans-serif; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: center}
.white {FONT-WEIGHT: bold; FONT-SIZE: 1em; COLOR: #ffffff; FONT-FAMILY: Arial, Helvetica, sans-serif; TEXT-ALIGN: left; TEXT-DECORATION: none}
.blue {FONT-WEIGHT: bold; FONT-SIZE: 1em; COLOR: #ffffff; FONT-FAMILY: Arial, Helvetica, sans-serif; TEXT-ALIGN: left; TEXT-DECORATION: none}
.Nav_Buttons {FONT-WEIGHT: bold; FONT-SIZE: 1em; COLOR: #000066; FONT-FAMILY: Arial, Helvetica, sans-serif; TEXT-ALIGN: left; TEXT-DECORATION: none}
.footer {FONT-SIZE: 0.7em; COLOR: #000000; FONT-FAMILY: Arial, Helvetica, sans-serif; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: center}
.style1 {color: #336699}
.style5 {color: #ffffff;
	font-weight: bold;
	font-family: Arial, Helvetica, sans-serif;}
</style>
<script language="JavaScript" type="text/javascript">
<!--
function mmLoadMenus() {
  if (window.mm_menu_0718104530_0) return;
  window.mm_menu_0718104530_0 = new Menu("root",174,17,"Arial, Helvetica, sans-serif",13,"#333333","#0000ff","#ffffcc","#ffffff","left","middle",2,0,1000,-5,7,true,true,true,0,true,true);
  mm_menu_0718104530_0.addMenuItem("Who&nbsp;We&nbsp;Are","location='http://www.fda.gov/cder/about/default.htm#Who We Are'");
  mm_menu_0718104530_0.addMenuItem("What&nbsp;We&nbsp;Do","location='http://www.fda.gov/cder/about/default.htm#What We Do'");
  mm_menu_0718104530_0.addMenuItem("What&nbsp;We've&nbsp;Accomplished","location='http://www.fda.gov/cder/about/default.htm#Accomplished'");
  mm_menu_0718104530_0.addMenuItem("Regulatory&nbsp;Authority","location='http://www.fda.gov/cder/about/default.htm#Regulatory Authority'");
  mm_menu_0718104530_0.addMenuItem("Feedback&nbsp;from&nbsp;Stakeholders","location='http://www.fda.gov/cder/about/default.htm#Feedback from Stakeholders'");
  mm_menu_0718104530_0.addMenuItem("Online&nbsp;Training","location='http://www.fda.gov/cder/learn/CDERLearn/default.htm'");
  mm_menu_0718104530_0.addMenuItem("CDER&nbsp;History","location='http://www.fda.gov/cder/about/history/default.htm'");
  mm_menu_0718104530_0.addMenuItem("Employment&nbsp;Opportunities","location='http://www.fda.gov/cder/career/default.htm'");
  mm_menu_0718104530_0.addMenuItem("How&nbsp;to&nbsp;Contact&nbsp;Us","location='http://www.fda.gov/cder/about/default.htm#How to Contact Us'");
   mm_menu_0718104530_0.hideOnMouseOut=true;
   mm_menu_0718104530_0.menuBorder=1;
   mm_menu_0718104530_0.menuLiteBgColor='#ffffcc';
   mm_menu_0718104530_0.menuBorderBgColor='#333333';
   mm_menu_0718104530_0.bgColor='#ffffcc';

  window.mm_menu_0718111254_0 = new Menu("root",141,17,"Arial, Helvetica, sans-serif",13,"#333333","#0000ff","#ffffcc","#ffffff","left","middle",2,0,1000,-5,7,true,true,true,0,true,true);
  mm_menu_0718111254_0.addMenuItem("New&nbsp;from&nbsp;CDER","location='http://www.fda.gov/cder/'");
  mm_menu_0718111254_0.addMenuItem("Recently&nbsp;Added&nbsp;Pages","location='http://www.fda.gov/cder/'");
  mm_menu_0718111254_0.addMenuItem("Quick&nbsp;Info&nbsp;Links","location='http://www.fda.gov/cder/'");
   mm_menu_0718111254_0.hideOnMouseOut=true;
   mm_menu_0718111254_0.menuBorder=1;
   mm_menu_0718111254_0.menuLiteBgColor='#ffffcc';
   mm_menu_0718111254_0.menuBorderBgColor='#333333';
   mm_menu_0718111254_0.bgColor='#ffffcc';

  window.mm_menu_0718111607_0 = new Menu("root",280,17,"Arial, Helvetica, sans-serif",13,"#333333","#0000ff","#ffffcc","#ffffff","left","middle",2,0,1000,-5,7,true,true,true,0,true,true);
  mm_menu_0718111607_0.addMenuItem("New&nbsp;Prescription&nbsp;Drug&nbsp;Approvals&nbsp;","location='http://www.fda.gov/cder/drug/default.htm#New Prescription Drug Approvals'");
  mm_menu_0718111607_0.addMenuItem("Prescription&nbsp;Drug&nbsp;Information","location='http://www.fda.gov/cder/drug/default.htm#Prescription Drug Information'");
  mm_menu_0718111607_0.addMenuItem("Major&nbsp;Drug&nbsp;Information&nbsp;Pages&nbsp;","location='http://www.fda.gov/cder/drug/default.htm#Major Drug Information Pages'");
  mm_menu_0718111607_0.addMenuItem("Consumer&nbsp;Drug&nbsp;Information","location='http://www.fda.gov/cder/drug/default.htm#Consumer Drug Information'");
  mm_menu_0718111607_0.addMenuItem("Over-the-Counter&nbsp;Drug&nbsp;Information","location='http://www.fda.gov/cder/Offices/OTC/default.htm'");
  mm_menu_0718111607_0.addMenuItem("Drug&nbsp;Safety&nbsp;&amp;&nbsp;Side&nbsp;Effects","location='http://www.fda.gov/cder/drug/default.htm#Drug Safety'");
  mm_menu_0718111607_0.addMenuItem("Drug&nbsp;Preparedness&nbsp;and&nbsp;Bioterrorism&nbsp;Response","location='http://www.fda.gov/cder/drugprepare/default.htm'");
  mm_menu_0718111607_0.addMenuItem("Clinical&nbsp;Trials&nbsp;Information","location='http://www.fda.gov/cder/drug/default.htm#Clinical Trials'");
  mm_menu_0718111607_0.addMenuItem("Public&nbsp;Health&nbsp;Alerts&nbsp;&amp;&nbsp;Warning&nbsp;Letters","location='http://www.fda.gov/cder/drug/default.htm#Public Health Alerts'");
  mm_menu_0718111607_0.addMenuItem("Reports&nbsp;&amp;&nbsp;Publications","location='http://www.fda.gov/cder/drug/default.htm#Reports & Publications'");
  mm_menu_0718111607_0.addMenuItem("Special&nbsp;Projects&nbsp;&amp;&nbsp;Programs","location='http://www.fda.gov/cder/drug/default.htm#Special Projects'");
   mm_menu_0718111607_0.hideOnMouseOut=true;
   mm_menu_0718111607_0.menuBorder=1;
   mm_menu_0718111607_0.menuLiteBgColor='#ffffcc';
   mm_menu_0718111607_0.menuBorderBgColor='#333333';
   mm_menu_0718111607_0.bgColor='#ffffcc';

  window.mm_menu_0718112003_0 = new Menu("root",210,17,"Arial, Helvetica, sans-serif",13,"#333333","#0000ff","#ffffcc","#ffffff","left","middle",2,0,1000,-5,7,true,true,true,0,true,true);
  mm_menu_0718112003_0.addMenuItem("Regulatory&nbsp;&amp;&nbsp;Scientific&nbsp;Guidances&nbsp;","location='http://www.fda.gov/cder/regulatory/default.htm#Regulatory'");
  mm_menu_0718112003_0.addMenuItem("Specific&nbsp;Regulatory&nbsp;Initiatives","location='http://www.fda.gov/cder/regulatory/default.htm#Specific Regulatory'");
  mm_menu_0718112003_0.addMenuItem("Legislation","location='http://www.fda.gov/cder/regulatory/default.htm#Legislation'");
  mm_menu_0718112003_0.addMenuItem("Prescription&nbsp;Drug&nbsp;User&nbsp;Fee&nbsp;Act&nbsp;","location='http://www.fda.gov/cder/pdufa/default.htm'");
  mm_menu_0718112003_0.addMenuItem("Submitting&nbsp;New&nbsp;Drug&nbsp;Applications","location='http://www.fda.gov/cder/regulatory/default.htm#Submitting Applications'");
  mm_menu_0718112003_0.addMenuItem("International&nbsp;Activities","location='http://www.fda.gov/cder/audiences/default.htm#International Activities'");
  mm_menu_0718112003_0.addMenuItem("CDER&nbsp;Policies&nbsp;&amp;&nbsp;Procedures","location='http://www.fda.gov/cder/mapp.htm'");
  mm_menu_0718112003_0.addMenuItem("Compliance&nbsp;Activities","location='http://www.fda.gov/cder/regulatory/default.htm#Compliance'");
  mm_menu_0718112003_0.addMenuItem("Freedom&nbsp;of&nbsp;Information&nbsp;Act","location='http://www.fda.gov/cder/foi/index.htm'");
  mm_menu_0718112003_0.addMenuItem("Useful&nbsp;Resources","location='http://www.fda.gov/cder/regulatory/default.htm#Useful Resources'");
   mm_menu_0718112003_0.hideOnMouseOut=true;
   mm_menu_0718112003_0.menuBorder=1;
   mm_menu_0718112003_0.menuLiteBgColor='#ffffcc';
   mm_menu_0718112003_0.menuBorderBgColor='#333333';
   mm_menu_0718112003_0.bgColor='#ffffcc';

  window.mm_menu_0718111847_0 = new Menu("root",224,17,"Arial, Helvetica, sans-serif",13,"#333333","#0000ff","#ffffcc","#ffffff","right","middle",2,0,1000,-5,7,true,true,true,0,true,true);
  mm_menu_0718111847_0.addMenuItem("Advisory&nbsp;Committee&nbsp;Meetings","location='http://www.fda.gov/cder/calendar/default.htm#Advisory Committee Meetings'");
  mm_menu_0718111847_0.addMenuItem("Meetings,&nbsp;Conferences&nbsp;&amp;&nbsp;Workshops","location='http://www.fda.gov/cder/calendar/default.htm#Meetings, Conferences & Workshops'");
  mm_menu_0718111847_0.addMenuItem("CDER&nbsp;Newsletter","location='http://www.fda.gov/cder/pike.htm'");
   mm_menu_0718111847_0.hideOnMouseOut=true;
   mm_menu_0718111847_0.menuBorder=1;
   mm_menu_0718111847_0.menuLiteBgColor='#ffffcc';
   mm_menu_0718111847_0.menuBorderBgColor='#333333';
   mm_menu_0718111847_0.bgColor='#ffffcc';

  window.mm_menu_0718111105_0 = new Menu("root",192,17,"Arial, Helvetica, sans-serif",13,"#333333","#0000ff","#ffffcc","#ffffff","right","middle",2,0,1000,-5,7,true,true,true,0,true,true);
  mm_menu_0718111105_0.addMenuItem("Consumer&nbsp;&amp;&nbsp;Patient&nbsp;Information","location='http://www.fda.gov/cder/audiences/default.htm#General Information'");
  mm_menu_0718111105_0.addMenuItem("Freedom&nbsp;of&nbsp;Information&nbsp;Act","location='http://www.fda.gov/cder/foi/index.htm'");
  mm_menu_0718111105_0.addMenuItem("International&nbsp;Activities","location='http://www.fda.gov/cder/audiences/default.htm#International Activities'");
  mm_menu_0718111105_0.addMenuItem("Pediatrics&nbsp;Initiatives","location='http://www.fda.gov/cder/pediatric/index.htm'");
  mm_menu_0718111105_0.addMenuItem("Small&nbsp;Business&nbsp;Assistance","location='http://www.fda.gov/cder/about/smallbiz/default.htm'");
  mm_menu_0718111105_0.addMenuItem("Spanish-Speaking","location='http://www.fda.gov/cder/audiences/default.htm#Spanish Speaking Audiences'");
   mm_menu_0718111105_0.hideOnMouseOut=true;
   mm_menu_0718111105_0.menuBorder=1;
   mm_menu_0718111105_0.menuLiteBgColor='#ffffcc';
   mm_menu_0718111105_0.menuBorderBgColor='#333333';
   mm_menu_0718111105_0.bgColor='#ffffcc';

  window.mm_menu_0718110309_0 = new Menu("root",237,17,"Arial, Helvetica, sans-serif",13,"#333333","#0000ff","#ffffcc","#ffffff","right","middle",2,0,1000,-5,7,true,true,true,0,true,true);
  mm_menu_0718110309_0.addMenuItem("Drug&nbsp;Information&nbsp;Approved&nbsp;Prior&nbsp;to&nbsp;1998","location='http://www.fda.gov/cder/archives/default.htm#Approved Prior to 1998'");
  mm_menu_0718110309_0.addMenuItem("Superseded&nbsp;Guidances","location='http://www.fda.gov/cder/archives/default.htm#Superceded Guidances'");
  mm_menu_0718110309_0.addMenuItem("Archival&nbsp;Reports&nbsp;&amp;&nbsp;Publications","location='http://www.fda.gov/cder/archives/default.htm#Archival Reports & Publications'");
   mm_menu_0718110309_0.hideOnMouseOut=true;
   mm_menu_0718110309_0.menuBorder=1;
   mm_menu_0718110309_0.menuLiteBgColor='#ffffcc';
   mm_menu_0718110309_0.menuBorderBgColor='#333333';
   mm_menu_0718110309_0.bgColor='#ffffcc';

  mm_menu_0718110309_0.writeMenus();
} // mmLoadMenus()
//-->
</script>
<script language="JavaScript1.2" src="/cder/templates/mm_menu.js" type="text/javascript"></script>
</head>
<body>
<div class="skip"> <a href="#top"><img src="/graphics/dot_clear.gif" alt="Skip Navigation" border="0" width="1" height="1" /></a></div>
<table cellspacing="0" cellpadding="4" width="80%" align="center" border="0">
  <tbody>
  <tr>
    <td valign="top" align="center" bgcolor="#ffffff">
      <table cellspacing="0" cellpadding="0" width="100%">
        <tbody>
        <tr>
          <td width="100" height="68"><a 
            href="http://www.fda.gov/default.htm">
          <img 
            alt="FDA Logo links to FDA home page" 
            src="../templates/Graphics/fda_graphics/fda_mast_01.gif" border="0" width="116" height="70"></a></td>
          <td width="50%" height="68"><img height="70" alt="  " 
            src="../templates/graphics/fda_graphics/fda_mast_bkgrd.gif" width="100%" 
border="0"></td>
          <td width="383" height="68">
            <div class=center>
              <img 
            alt="Center for Drug Evaluation and Research, U.S. Food and Drug Administration" 
            src="../templates/graphics/fda_graphics/fda_cder_02.gif" 
            usemap=#fda_cber_02bb13509b border="0" width="383" height="70"><map 
              name=fda_cber_02bb13509b><area shape=RECT 
              alt="U.S. Food and Drug Administration" coords="3,16,378,44" 
              href="http://www.fda.gov/default.htm"><area shape=RECT 
              alt="Center for Drug Evaluation and Research" coords="8,55,374,69" 
              href="http://www.fda.gov/cder/"></map></div></td>
          <td width="52%" height="68"><img height="70" alt="  " 
            src="../templates/Graphics/fda_graphics/fda_mast_bkgrd.gif" width="100%" 
border="0"></td>
          <td width="116" height="68"><a href="http://www.hhs.gov/">
          <img 
            alt="HHS Logo links to Department of Health and Human Services website" 
            src="../templates/graphics/fda_graphics/fda_mast_03.gif" 
        border="0" width="116" height="70"></a></td></tr>
        <tr>
          <td colspan="5"><table cellspacing=0 cellpadding=0 width="100%">
                  <tbody>
                    <tr>
                      <td colspan=5><p class=header><a href="http://www.fda.gov/default.htm">FDA 
                          Home Page</a> | <a href="http://www.fda.gov/cder">CDER 
                          Home Page</a> | <a href="http://www.fda.gov/cder/site/default.htm">CDER 
                          Site Info</a> | <a 
                  href="http://www.fda.gov/cder/comment.htm">Contact CDER </a>| <a 
                  href="http://www.fda.gov/cder/whatsnew.htm">What's New @ CDER</a></p>
                        <img 
                  height=1 alt="horizonal rule" 
                  src="../templates/Graphics/blkpixel.gif" width="100%" 
              border=0></td>
                    </tr>
                  </tbody>
                </table></td>
            </tr>
            <tr>
              <td valign="middle" align="center" bgcolor=#ffffff colspan=5 
            height=10><img height=5 alt=" " 
            src="../templates/Graphics/dot_clear.gif" width="97%" 
        border=0></td>
            </tr>
          </tbody>
        </table>
        <table cellspacing=0 cellpadding=0 width="100%" align=center border=0>
          <tbody>
            <tr>
              <td width="50%"><table cellspacing=0 cellpadding=0 width="100%" border=0>
                  <tbody>
                    <tr>
                      <td><img height=32 
                  src="../templates/Graphics/Sm_Button_Bottom_Line.gif" 
                  width="100%"></td>
                    </tr>
                  </tbody>
                </table></td>
              <td><table id=buttons cellspacing=0 cellpadding=0 width=626 align=center 
            border=0>
                  <tbody>
                    <tr>
                      <td width=86><a href="http://www.fda.gov/cder/" onMouseOut="MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_0718111254_0,0,33,null,'Sm_Button_Home_Off');"><img src="http://www.fda.gov/cder/templates/graphics/Sm_Button_Home_On.gif" alt="CDER Home" name="Sm_Button_Home_Off" width="86" height="32" border="0" align="top"></a></td>
                      <td width=91><script language="JavaScript1.2">mmLoadMenus();</script>
                        <a onMouseOut="MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_0718104530_0,0,33,null,'Sm_Button_About_Off');" href="http://www.fda.gov/cder/about/default.htm"><img src="http://www.fda.gov/cder/templates/graphics/Sm_Button_About_On.gif" alt="About CDER" name="Sm_Button_About_Off" width="91" height="32" border="0" align="top"></a> </td>
                      <td width=90><a onMouseOut="MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_0718111607_0,0,33,null,'Sm_Button_DrugInfo_Off');" href="http://www.fda.gov/cder/drug/default.htm"><img src="http://www.fda.gov/cder/templates/graphics/Sm_Button_DrugInfo_On.gif" alt="Drug Information" name="Sm_Button_DrugInfo_Off" width="90" height="32" border="0" align="top"></a></td>
                      <td width=92><a onMouseOut="MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_0718112003_0,0,33,null,'Sm_Button_Regulatory_Off');" href="http://www.fda.gov/cder/regulatory/default.htm"><img src="http://www.fda.gov/cder/templates/graphics/Sm_Button_Regulatory_On.gif" alt="Regulatory Guidance" name="Sm_Button_Regulatory_Off" width="92" height="32" border="0" align="top"></a></td>
                      <td width=90><a href="http://www.fda.gov/cder/calendar/default.htm" onMouseOut="MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_0718111847_0,-135,33,null,'Sm_Button_Calendar_On');"><img src="http://www.fda.gov/cder/templates/graphics/Sm_Button_Calendar_On.gif" alt="CDER Calendar" name="Sm_Button_Calendar_On" width="90" height="32" border="0" align="top"></a></td>
                      <td width=90><a onMouseOut="MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_0718111105_0,-104,33,null,'Sm_Button_Audiences_Off');" href="http://www.fda.gov/cder/audiences/default.htm"><img src="http://www.fda.gov/cder/templates/graphics/Sm_Button_Audiences_On.gif" alt="Specific Audiences" name="Sm_Button_Audiences_Off" width="90" height="32" border="0" align="top"></a></td>
                      <td width=87><a href="http://www.fda.gov/cder/archives/default.htm" onMouseOut="MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_0718110309_0,-155,33,null,'Sm_Button_Archives_Off');"><img src="http://www.fda.gov/cder/templates/graphics/Sm_Button_Archives_On.gif" alt="CDER Achives" name="Sm_Button_Archives_Off" width="87" height="32" border="0" align="top"></a></td>
                    </tr>
                  </tbody>
                </table></td>
              <td width="50%"><img height=32 
            src="../templates/Graphics/Sm_Button_Bottom_Line.gif" 
        width="100%"></td>
            </tr>
          </tbody>
        </table>
        <table cellspacing=0 cellpadding=0 width="100%" align=center border="0">
          <tbody>
            <tr>
              <td valign="middle" align="center" bgcolor=#ffffff height=10><img 
            height=5 alt=" " src="../templates/Graphics/dot_clear.gif" width="97%" 
            border=0></td>
            </tr>
          </tbody>
        </table>
        <div align=left>
          <table cellspacing=0 cellpadding=0 width="100%" bgcolor=#ffffff 
        border=0>
            <tbody>
              <tr>
                <td valign=bottom width=153><table bordercolor="#000066" cellspacing=0 cellpadding=0 width=153 
            bgcolor=#ffffff border=0>
                    <tbody>
                      <tr>
                        <td><table width="153" border="0" cellpadding="0" cellspacing="0" bordercolor="#000066" bgcolor="#FFFFFF">
                            <tr>
                              <td><div align="center"> <img src="../templates/Graphics/LogoCDER_WhtBG.gif" width="123" height="43"></div></td>
                            </tr>
                          </table></td>
                      </tr>
                    </tbody>
                  </table></td>
                <td valign=bottom width=100%><div align=left>
                    <table width="90%" border="0" align="center" cellpadding="5" cellspacing="0">
                      <tr>
                        <td><span class="header3"><span style="background-color: #FFFFFF"><span class="style1"><a name="top"></a>Office of Generic Drugs</span></span></span><font color="#336699"><span class="header3"><span style="background-color: #FFFFFF"><br>
                          &nbsp;</span></span></font></td>
                      </tr>
                    </table>
                  </div></td>
                <td valign=bottom width=10><img height=2 
            src="../templates/Graphics/dot_clear.gif" 
      width="100%"></td>
              </tr>
            </tbody>
          </table>
          <table cellspacing=0 cellpadding=0 width="100%" bgcolor=#ffffff 
        border=0>
            <tbody>
              <tr>
                <td width=6><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=153><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=515><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=8><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
              </tr>
              <tr>
                <td width=6><img height=2 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=153><img height=2 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width="100%"><img height=2 src="../templates/Graphics/redline.gif" 
            width="100%"></td>
                <td width=8><img height=2 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
              </tr>
              <tr>
                <td width=6><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=153><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=515><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=8><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
              </tr>
              <tr>
                <td width=6><img height=2 src="../templates/Graphics/dot_clear.gif" 
            width=1></td>
                <td width=153 valign=top background="../templates/Graphics/fill5.gif" bgcolor="#336699"><table id="Navigation Table"  cellspacing=0 
            cellpadding=5 width=153 align=center border=1>
                    <tbody>
                     <tr>
                      <td bgcolor=#000066 align=left class="style5">OGD</td>
                      </tr>
                      <tr>
                       <td background="../templates/Graphics/Flag_BG1.jpg">
                       <p>&nbsp;</p>
                       <p class="Nav_Buttons"><a href="#Introduction">What are Generic Drugs?</a></p>
                       <p class="Nav_Buttons"><a href="#Available">Is a Generic Drug Available for a Brand Name Drug?</a></p>
                       <p class="Nav_Buttons"><a href="#New"> News and Announcements</a><br><br></p></td>
                      </tr>
                      <tr>
                        <td bgcolor=#000066  align=left><span class="Nav_Buttons"> <a href="#Contact"> <font color="#FFFFFF">How to Contact Us</font></a></span> </td>
                      </tr>
                    </tbody>
                  </table></td>
            <td valign=top width="100%">

 <table cellspacing=0 cellpadding=5 width="95%" align=center border=0>
  <tbody>
   <tr>
    <td><table border="1" width="100%" bordercolor="#FFFFFF">
     <tr>
      <td width="100%">
       <p align="center"><a href="#mailaddress">The Office of Generic Drugs Mailing Address</a> </p>
       <ul>
         <li><a href="welcome_to_ogd.htm">Welcome from Office of Generic Drugs' Director</a></li>
          <li><a href="#Introduction">What are Generic Drugs?</a>
         <ul>
            <li><a href="../consumerinfo/generics_q&amp;a.htm">Generic Drugs: Questions and Answers</a></li>
         </ul>
         </li>
         <li><a href="#Available">Is a Generic Product Available for a Brand Name Drug?</a></li>
         <li><a href="QbR.htm">Question based Review (QbR) for Chemistry, Manufacturing, and Controls (CMC) evaluation of an Abbreviated New Drug Application (ANDA)</a></li>
         <li><a href="#New">News and Announcements</a> <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (12/18/2008)
           <ul>
            <li><a href="#Recent">Recent <i>Federal Register </i> Notices</a></li>
           </ul>
          </li>
         <li><a href="#Approvals">Generic Drug Approvals</a> <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (2/3/2009)</li>
          <li><a href="#Authorized">List of Authorized Generic Drugs </a><img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (12/22/2008) </li>
         <li><a href="#enumber">Requesting an Electronic Common Technical Document (eCTD) Number</a> <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (5/28/2008)</li>
         <li><a href="#Therapeutic Equivalence">Therapeutic Equivalence of Generic Drugs</a> </li>
         <li><a href="http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm">Dissolution Methods for Drug Products</a> </li>
         <li><a href="#anda">Generic Drug Development, Abbreviated New Drug Application (ANDA) Submissions and Review Information</a>
           <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (8/20/2008)
           <ul>
              <li><a href="#bioequivalence">Model Bioequivalence Data Summary Tables</a></li>
            </ul>
         </li>
         <li><a href="#Laws">Regulations for Abbreviated New Drug Application Submissions</a></li>
         <li><a href="#paragraph">Paragraph IV Drug Product Applications</a> <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (2/2/2009)</li>
         <li><a href="#Petition">Generic Drug Petition Tracking</a> <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (8/18/2008)</li>
         <li><a href="#Org">Organization and Contact Information</a> <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (12/17/2008)</li>
         <li><a href="#FOI">Freedom of Information</a></li>
         <li><a href="#Contact">How to Contact Us</a></li>
       </ul></td>
     </tr>
   </table>
       
      <table border="0" width="100%">
        <tr>
         <td width="100%" bgcolor="#CAEEFD"><h3 class="style7"><a name="Introduction"><strong>What are Generic Drugs?</strong></a></h3></td>
        </tr>
       </table>
       
          <p>A generic drug is identical, or bioequivalent to a
                                brand name drug in dosage form, safety, strength, route of administration, quality,
                                performance characteristics and intended use.&nbsp; Although generic
                                drugs are chemically identical to their branded counterparts, they are typically sold at
                                substantial discounts from the branded price.&nbsp;According to the Congressional Budget
                                Office, generic drugs save consumers an estimated $8 to $10 billion a year at retail
                                pharmacies.&nbsp; Even more billions are saved when hospitals use generics.</p>
                                
          <p>Drug companies must submit an abbreviated new drug application (ANDA) for approval to market a generic product.&nbsp; The <a href="../about/smallbiz/patent_term.htm">Drug Price Competition and Patent Term
                                Restoration Act of 1984</a>, more commonly known as the Hatch-Waxman
                                Act, made ANDAs possible by creating a compromise in the drug industry. Generic drug
                                companies gained greater access to the market for prescription drugs, and innovator
                                companies gained restoration of patent life of their products lost during FDA's approval
                                process.</p>
                                
          <p>New drugs, like other new products, are developed
                                under patent protection.&nbsp; The patent protects the investment in the drug's
                                development by giving the company the sole right to sell the drug while the patent is in
                                effect.&nbsp; When patents or other periods of exclusivity expire, manufacturers can apply
                                to the FDA to sell generic versions.&nbsp; The ANDA process does not require the drug
                                sponsor to repeat costly animal and clinical research on ingredients or dosage forms
                                already approved for safety and effectiveness.&nbsp; This applies to drugs first marketed
                                after 1962.</p>
     
     <p>Health professionals and consumers can be assured that FDA approved generic drugs have met the same rigid standards as the innovator drug. To gain FDA approval, a generic drug must:</p>
     
         <ul>
          <li>contain the same active ingredients as the innovator drug(inactive ingredients may vary)</li>
          <li>be identical in strength, dosage form, and route of administration</li>
          <li>have the same use indications</li>
          <li>be bioequivalent</li>
          <li>meet the same batch requirements for identity, strength, purity, and quality</li>
          <li>be manufactured under the same strict standards of FDA's good manufacturing practice regulations required for innovator products</li>
         </ul>
            <p>For more information on the safety and effectiveness of generic drugs, please see:</p>
        <ul>
          <li><a href="http://www.fda.gov/oc/initiatives/generics">FDA Generic Drugs Final Rule and Initiative</a></li>
          <li><a href="../consumerinfo/generic_text.htm">Consumer Education: Generic Drugs</a></li>
          <li><a href="generic_competition.htm">Generic Competition and Drug Prices</a> (4/4/2006)<br></li>
          <li>FDA White Paper: <a href="http://www.fda.gov/oc/initiatives/generics/whitepaper.html"> New FDA Initiative on &quot;Improving Access to Generic Drugs.&quot;</a> (6/12/2003).</li>
          <li>FDA White Paper: <a href="http://www.fda.gov/oc/whitepapers/drugprices.html">Generic Drug Prices in the U.S. Are Lower Than Drug Prices in Canada</a>. (11/2003)</li>
          <li>FDA and the Drug Development Process: How the Agency Ensures that Drugs are Safe and Effective (2/2002) [<a href="http://www.fda.gov/opacom/factsheets/justthefacts/17drgdev.html">HTML</a>] or [<a href="http://www.fda.gov/opacom/factsheets/justthefacts/17drgdev.pdf">PDF</a>]. Spanish version: [<a href="http://www.fda.gov/opacom/factsheets/justthefacts/17drgdevsp.html">HTML</a>] or [<a href="http://www.fda.gov/opacom/factsheets/justthefacts/17drgdevsp.pdf">PDF</a>]</li>
          <li><a href="../about/whatwedo/testtube-17.pdf">FDA Ensures Equivalence of Generic Drugs</a><small>. </small> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"> From the 1999 edition of &quot;From Test Tube to Patient: Improving health through human drugs.&quot;</li>
          <li>Generic Drugs: <a name="Safe. Effective">Safe. Effective</a>. FDA Approved. Public service announcements promoting the safety and effectiveness of generic drugs.
            <ul>
              <li><a href="../consumerinfo/generic_all_resources.htm">Six Public Service Announcements</a></li>
            </ul>
          </li>
        </ul>
        
   <table border="0" width="100%">
     <tr>
      <td width="100%" bgcolor="#CAEEFD"><h3 class="style7"><a name="Available"><strong>Is a Generic Drug Available for a Brand Name Drug?</strong></a></h3></td>
      </tr>
     </table>
     
          <p>You can search for generic equivalents by using the <a href="../ob/default.htm">&quot;Electronic Orange Book&quot;</a> and search by proprietary &quot;brand&quot; name,&quot; then search again by  using the active ingredient name. If other manufacturers are  listed besides the &quot;brand name&quot; manufacturer when searching by the &quot;active ingredient,&quot; they are the generic product manufacturers.</p>
          
          <p>Since there is a lag time after generic products are approved and they appear in the &quot;Orange Book,&quot; you should also consult the most recent monthly approvals for <a href="approvals/default.htm">&quot;First Generics&quot;</a>.</p>
                              
          <p><small><a href="#top">Back to Top</a></small></p>
          
   <table border="0" width="100%">
     <tr>
       <td width="100%" bgcolor="#CAEEFD"><h3 class="style7"><a name="New"><strong>News and Announcements</strong></a></h3></td>
     </tr>
     </table>
 
         <ul>
         <li><a href="090014698029b1e7.pdf">FDA's clarification of Dorzolamide Hydrochloride 2%/Timolol Maleate 0.5% Ophthalmic Solution Exclusivity </a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"><br>
             <br></li>
         
          <li><a href="residualsolvents.pdf">Residual Solvents in ANDAs: Questions and Answers</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"><br>
             <br>
          </li>
          <li><a href="http://www.pharmaconference.com/pharmaceutical_conferences/p_conf_brochures/6-08%20REVISEDBethesda%20.pdf">FDA and Generic Drugs: An Interactive Forum</a><br>
            A special FDA conference for industry, co-sponsored by the University of Rhode Island, College of Pharmacy, focusing on effective communications, addressing ANDA deficiencies and the current legal landscape regarding ANDAs.<br><br></li>
          
          <li><a href="../drug/infopage/bupropion/TE_review.htm">CDER issues &quot;Review of Therapeutic Equivalence  Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg&quot;</a><br>
                    <br></li>
          <li>Decisions related to PUBLIC LAW 108&ndash;173, DEC. 8, 2003, <strong>Medicare Prescription Drug, Improvement, and Modernization Act (MMA)</strong> of 2003
            <ul>
              <li><a href="http://www.fda.gov/ohrms/dockets/DOCKETS/07n0389/07n-0389-let0003.pdf">Determination of Ganisetron Exclusivity</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"></li>
                  <li><a href="09001469801b7d1f.pdf">Determination of Ramipril Exclusivity</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"></li>
                  <li><a href="http://www.regulations.gov/fdmspublic/component/main?main=DocumentDetail&o=090000648055265c">Determination of Acarbose  Exclusivity</a> (click on PDF icon on the Regulations.gov web page) </li>
                  <li><a href="http://www.regulations.gov/search/search_results.jsp?css=0&&Ntk=All&Ntx=mode+matchall&Ne=2+8+11+8053+8054+8098+8074+8066+8084+8055&N=0&Ntt=dorzolamide&sid=11E4B5155292">Determination of Dorzolamide-Timolol Maleate Ophthalmic Solution Exclusivitiy</a> (click on PDF icon on the Regulations.gov web page) <img src="../graphics/new.gif" alt="New!!" width="37" height="11"><br>
                    <br>
                  </li>
            </ul>
          </li>
          <li>FDA requests comments regarding the <!--<a href="http://www.regulations.gov/fdmspublic/wdk/theme/documentum/icons/format/f_pdf_16.gif">http://www.regulations.gov/fdmspublic/wdk/theme/documentum/icons/format/f_pdf_16.gif</a>--> forfeiture of 180-day generic-drug exclusivity for acarbose under Title XI of the MEDICARE PRESCRIPTION DRUG,IMPROVEMENT, AND MODERNIZATION ACT OF 2003 (MMA). All comments should be submitted to Docket No. <a href="http://www.fda.gov/ohrms/dockets/dockets/07n0417/07n0417.html">2007N-0417</a>. FDA has extended the deadline for response until November 12, 2007. <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"><br>
              <br>
          </li>
          <li>FDA has established Docket No. <a href="http://www.fda.gov/ohrms/dockets/DOCKETS/07n0389/07n0389.html">2007N-0389</a> for comments regarding 180-day generic drug exclusivity for granisetron hydochloride injection.  Anyone wishing to comment on this subject should submit their comments to the FDA's Division of Dockets Management and reference the docket number.  FDA will be accepting comments until October 31th, 2007. The submission will be on public display in the Divison of Dockets Management, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852. <br>
            <br></li>
                                        
           <li><a href="http://www.fda.gov/oc/initiatives/advance/generics.html">Generic Initiative for Value and Efficiency (GIVE)</a><br>
             <br></li>
           
           <li>FDA has established Docket No.   <a href="http://www.fda.gov/ohrms/dockets/DOCKETS/07n0382/07n0382.htm">2007N-0382</a>   for comments regarding 180-day generic drug exclusivity for ramipril capsules.  Anyone wishing to comment on this subject should submit their comments to the FDA's Dockets Management Branch and reference the docket number. FDA will be accepting comments until October 19th, 2007. The submission will be on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD  20852. <br>
             <br></li>
           
             <li>Beginning October 1, 2007, all newly received Abbreviated New Drug Applications (ANDAs) will be numbered sequentially in the 90-000 series including those that previously would have been numbered in the 40-000, 60-000, 70-000 and 80-000 series.  This will further streamline the receiving process for ANDAs. <br>
              <br></li>
            
          <li><a href="../guidance/bioequivalence/default.htm">Guidance for Industry: Individual Product   Bioequivalence Recommendations</a><br><br></li>
          
         <li><a href="http://www.fda.gov/ohrms/dockets/dockets/07n0123/07n0123.htm">FDA addresses issues on Amlodipine Abbreviated New Drug Application Approvals</a><br><br></li>
         
         <li><a href="OrangeBookFRSafetyorEffectivenessDeterminationsList.pdf">Orange Book FR Safety or Effectiveness Determinations List</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"> <img src="../graphics/updated.gif" alt="updated " border="0" width="46" height="12"> (7/22/2008) The following is a list of approved drug products that have had Federal Register Citizen Petition Notices stating that the FDA has determined that the approved drug product was not discontinued for safety or effectiveness reasons.  Under &sect; 314.161(a)(1) [21 CFR 314.161(a)(1)], the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness before an ANDA that refers to that listed drug may be approved.  FDA may not approve an ANDA that does not refer to a listed drug.  The Federal Register Notice will allow FDA to approve applications (ANDAs) for the product if all other legal and regulatory requirements are met.  The list is from 1995. <br><br></li>
                
        <li>FDA Notifies Pharmaceutical Companies to Confirm or Repeat  Analytic Studies Used in the Approval of a Number of Drug Products. <a href="../news/pharmaco_studies/default.htm">Information</a> (1/10/2007)<br><br></li>
                
       <li>Manual of Policies and Procedures (MaPP): <a href="http://www.fda.gov/cder/mapp/5240-3R.pdf">5240.3R  Review Order of Original ANDAs, Amendments, and Supplements</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"><br><br></li>
       
        <li><a href="announce/aripiprazole_04-1010_corr2.pdf">FDA's Clarification of Aripiprazole Tablets' Bioequivalence Requirements</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"><br><br></li>
     
       <li><a href="announce/simvastatin_appl_upd.pdf">FDA's Clarification of the Patent Status for Simvastatin</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"><br><br></li>
       
       <li><a href="announce/Pravastatin-180Day-amend.pdf">FDA's Clarification of  Pravastatin's Exclusivity</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"><br><br></li>
                
      <li>Presentations from the Generic Pharmaceutical Association's 2006 Annual Meeting Business Exposition, February 16-18, 2006. (3/7/2006)
         <ul>
           <li><a href="announce/2006_02_18GJB_GPhA.pdf">&quot;Update from the Office of Generic Drugs&quot;</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16">, Gary J. Buehler, Director, Office of Generic Drugs. </li>
           
           <li><a href="announce/2006_02_17JB_GphaTAC.pdf">&quot;Update to the GPhA Technical Advisory Committee&quot;</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16">, Gary J. Buehler, Director, Office of Generic Drugs.</li>
           
           <li><a href="announce/2006_02_16_TC_GPhA_v3.pdf">&quot;Regulatory Assessment of Pharmaceutical Quality for Generic Drugs&quot;</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16">, Lawrence Yu, Ph.D., Director for Science, Office of Generic Drugs.</li>
                 
          <li><a href="announce/Labeling_Updates.pdf">&quot;Generic Labeling 2006&quot;</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16">, Koung Lee, Reviewer, Labeling Review Branch, Division of Labeling and Program Support, Office of Generic Drugs.<br><br></li>
      </ul>
       </li>
       
      <li><a href="previousItems.htm#news">Previous News items</a></li>
       </ul>
       
        <table border="0" width="100%">
         <tr>
          <td width="100%" bgcolor="#D3FBFC"><h3 class="style7"><strong>Recent Court Decisions</strong></h3></td>
          </tr>
            </table>
            
            <ul>
          <li>No recent court decisions</li>
            </ul>
            
        <table border="0" width="100%">
          <tr>
            <td width="100%" bgcolor="#D3FBFC"><h3 class="style7"><strong><a name="Recent"></a><span class="style7">Recent <em>Federal Register</em> Notices</span></strong></h3></td>
            </tr>
            </table>
            
            <ul>
          <li>Food and Drug Administration [Docket No. 2005N-0331] Able  Laboratories, Inc.; Withdrawal of Approval of Ten Abbreviated New  Drug Applications [<a href="http://www.fda.gov/OHRMS/DOCKETS/98fr/05-17151.htm">TXT</a>] [<a href="http://www.fda.gov/OHRMS/DOCKETS/98fr/05-17151.pdf">PDF</a>] (8/29/2005)<br><br>
          
        Summary: The Food and Drug Administration (FDA) is withdrawing approval of ten abbreviated new drug applications (ANDAs) held by  Able Laboratories, Inc. (Able Labs), One Able Dr., Cranbury, NJ 08512. Able Labs has initiated a class II recall of the products covered by these ANDAs. The company has requested that the applications be withdrawn and has waived its opportunity for a hearing.<br><br></li>
        
          <li>Food and Drug Administration [Docket No. 2005D-0312] Draft Guidance for Industry on Abbreviated New Drug Applications: Impurities in Drug Products; Chemistry, Manufacturing, and Controls Information; Availability [<a href="http://www.fda.gov/OHRMS/DOCKETS/98fr/05-17150.htm">TXT</a>] [<a href="http://www.fda.gov/OHRMS/DOCKETS/98fr/05-17150.pdf">PDF</a>] (8/29/2005)
            <ul>
              <li>The Draft Guidance [<a href="http://www.fda.gov/OHRMS/DOCKETS/98fr/05d-0312-gdl0001.pdf">PDF</a>]</li>
            </ul>               
          </li>
            </ul>
            
            <blockquote>
          <p>Summary: The Food and Drug Administration (FDA) is announcing the 
                                        availability of a draft guidance for industry entitled ''ANDAs: 
                                        Impurities in Drug Products; Chemistry, Manufacturing, and Controls 
                                        Information.'' This draft guidance provides recommendations on what 
                                        chemistry, manufacturing, and controls information sponsors should 
                                        include regarding reporting, identification, qualification, and 
                                        setting acceptance criteria for impurities that are classified as 
                                        degradation products in drug products when submitting an abbreviated 
                                        new drug application (ANDA) or supplement to support changes in drug 
                                        substance synthesis or process, formulation of the drug product, the 
                                        manufacturing process, or components of the container/closure 
                                        system. </p>
            </blockquote>
            
          <ul>
          <li><a href="previousItems.htm#FR">Previous<i> Federal Register</i> items </a></li>
          </ul>
            
          <p><small><a href="#top">Back to Top</a></small></p>
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><a name="Approvals"><strong> Generic Drug Approvals</strong></a></h3></td>
        </tr>
          </table>
                
       <ul>
          <li>The monthly <a href="approvals/default.htm">Generic Drug Approvals List</a>&nbsp; includes approvals, first-time generics, and tentative approvals.</li>
            </ul>
             <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><a name="Authorized">List of Authorized Generic Drugs</a></h3></td>
        </tr>
          </table>
                
       <ul>
          <li>The quarterly <a href="AuthorizedGenerics.htm">List of Authorized Generic Drugs</a>    includes the drug trade name, the brand company   manufacturer, and  the date the authorized generic drug entered the market.</li>
            </ul>
             <p><small><a href="#top">Back to Top</a></small></p>
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><a name="enumber"><strong>Requesting an Electronic Common Technical Document (eCTD) Number</strong></a></h3></td>
        </tr>
          </table>
          
       <ul>
          <li>Step-by-step description of how to <a href="../regulatory/ersr/preassigned_application.htm">request an eCTD number</a> from OGD.</li>
            <li>You may request a pre-assigned number, ONLY when you are submitting a NEW eCTD ANDA.  If you are converting an established ANDA to eCTD, you MUST use the original ANDA application number.</li>
             <li>If submitting a paper ANDA, do NOT request a pre-assigned number.<br>
             </li>
             <li>If you have any comments or questions, please contact:<br>
               Gerrard Cuthbert<br>
               301-796-3981  </li>
             <a href="mailto:gerrard.cuthbert@fda.hhs.gov">gerrard.cuthbert@fda.hhs.gov</a><br>
            </li>
       </ul>
            
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><a name="Therapeutic Equivalence"><strong>Therapeutic Equivalence of Generic Drugs</strong></a></h3></td>
        </tr>
          </table>
         <ul>
          <li><a name="levothyroxine_TE"></a> (8/9/2005) Therapeutic Equivalence between Levothyroxine Sodium drug 
                                        products. &nbsp;Because there are multiple reference listed drugs 
                                        of levothyroxine sodium tablets and some reference listed drugs' 
                                        sponsors have conducted studies to establish their drugs' therapeutic 
                                        equivalence to other reference listed drugs, FDA has determined that 
                                        its usual practice of assigning two or three character TE codes may be 
                                        potentially confusing and inadequate for these drug products. 
                                        Accordingly, FDA provides the following explanation and chart of 
                                        therapeutic equivalence evaluations for levothyroxine sodium drug 
                                        products. See <a href="http://www.fda.gov/cder/orange/obannual.pdf"> Annual Edition </a> <img border="0" src="../graphics/pdf.gif" width="16" height="16">. Select Bookmark 1.8 
                                        Description of Special Situations for a complete explanation of the 
                                        therapeutic equivalencies and chart.<br><br></li>
                                        
         <li><a href="http://www.fda.gov/cder/news/nightgenlett.htm">Therapeutic Equivalence of                                        Generic Drugs Letter to Health Practitioners</a> (2/4/1998) This letter
                                        addresses therapeutic equivalence between generic and innovator drug products.<br></li>
                                        
          <li><a href="http://www.fda.gov/cder/news/ntiletter.htm">Therapeutic Equivalence of Generic
                                        Drugs Response to National Association of Boards of Pharmacy</a> (2/6/1998) This letter provides background information, and answers to questions on narrow
                                        therapeutic drugs and their substitutability.<br></li>
                                        
          <li><em><a href="http://www.fda.gov/cder/ob/default.htm">Approved Drug Products with
                                        Therapeutic Equivalence Evaluations (Orange Book)</a> </em> The <em>Orange
                                        Book</em> lists approved drug products that are bioequivalent, including new drugs,
                                        generic drugs, and antibiotics. Approved nonprescription products are also in the <em>Orange Book</em> along with information about patents and periods of marketing exclusivity.</li>
            </ul>
          
                    <p><small><a href="#top">Back to Top</a></small></p>
                    
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3 class="style7"><a name="anda"><strong>Generic Drug Development, Abbreviated New Drug Application (ANDA) Submissions, and Review Information</strong></a></h3></td>
        </tr>
          </table>
                    <ul>
          <li><a name="bioequivalence"></a>Model Bioequivalence Data Summary Tables. [<a href="DBE_tables.pdf">PDF</a>] [<a href="DBE_tables.doc">Word</a>]&nbsp;   The Division of Bioequivalence has developed new data summary tables so that data can be submitted to the Office of Generic Drugs in a concise format consistent with the Common Technical Document.  ANDA applicants should complete these tables and send the completed tables along with the rest of the Bioequivalence submission of their ANDA. There are instructions with the tables explaining how to fill them out. <a href="Summary_BioTables_CTD.htm">Common Technical Document (CTD) Modules/Sections Corresponding to Summary Data Tables in Bioequivalence Submissions to ANDAs </a><br>
            <br></li>
          
          <li>ANDA Checklist for Completeness and Acceptability [<a href="anda_checklist.pdf">PDF</a>] [<a href="anda_checklist.doc">Word</a>]  Note:  In Sections  3.2.S.2.1 and 3.2.P.3.1, it is critically important that  the correct Name, Full Address and establishment contact information of the manufacturing or testing facility location be included (not the corporate address).  Additionally, the correct FDA Establishment Identifier number (FEI)  or Central File Number (CFN) for the exact facility must be included. 
            <br>
            <br></li>
          
          <li><a href="http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm">Inactive Ingredient
                                        Database</a> The newly revised Inactive Ingredients Database
                                        provides information on inactive ingredients present in FDA-approved
                                        drug products. This information can be used by industry as an aid in
                                        developing drug products.</li>
            </ul>
            <ul>
          <li><a href="retention_samples.htm">Bioequivalence Study Retention Samples</a>.
                                        (1/12/2001)&nbsp; Regulations state that applicants shall retain reserve samples of the tested products administered to study subjects and release these samples to FDA upon request. The Agency may then analyze these retention samples to ensure that the BA/BE results upon which FDA bases approval of New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDAs) are reliable.<br><br></li>
                                        
          <li><a href="../regulatory/applications/anda.htm">Abbreviated New Drug Application Process</a>. This web page includes all the information needed to assist with preparing and submitting ANDAs.<br><br></li>
          
          <li><a href="../guidance/index.htm">FDA
                                        Letters to Industry</a>&nbsp; This series of letters informs generic drug product
                                        manufacturers of policy and procedure developments with respect to the Drug Price
                                        Competition and Patent Term Restoration Act of 1984.<br>
                            <br></li>
                                        
          <li><a href="http://www.fda.gov/cder/handbook/anda.htm">Generic Drug Review Process</a>.&nbsp; An interactive chart that provides an overview of CDER's abbreviated new drug application (ANDA) review process, and how CDER determines the safety and bioequivalence of generic drug products prior to approval for marketing.</li>
            </ul>
            
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD" valign="middle"><h3><a name="Laws"><strong>Regulations for Abbreviated New Drug Application Submissions</strong></a></h3></td>
        </tr>
          </table>
        <table border="0" width="100%">
          <tr>
            <td width="100%" bgcolor="#D3FBFC"><strong><em>Code of Federal Regulations</em></strong></td>
          </tr>
            </table>
            
            <ul>
          <li><a href="http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi?TITLE=21&amp;PART=2&amp;SECTION=125&amp;YEAR=1999&amp;TYPE=TEXT">CFR  2.125</a>&nbsp; Use of chlorofluorocarbon propellants in self-pressurized containers</li>
          <li><a href="http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi?TITLE=21&amp;PART=5&amp;SECTION=80&amp;YEAR=1999&amp;TYPE=TEXT">CFR
21 5.80</a>&nbsp; Approval of new drug applications and their supplements</li>
          <li><a href="http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi?TITLE=21&amp;PART=10&amp;SECTION=30&amp;YEAR=1998&amp;TYPE=TEXT">CFR
21 10.30</a>&nbsp; Citizen Petition</li>
          <li><a href="http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi?TITLE=21&amp;PART=10&amp;SECTION=45&amp;YEAR=1998&amp;TYPE=TEXT">CFR
 21 10.45</a>&nbsp; Court review of final administrative action; exhaustion of administrative remedies</li>
          <li><a href="http://www.access.gpo.gov/nara/cfr/waisidx_99/21cfr50_99.html">CFR 21 50</a>&nbsp; Protection of Human Subjects</li>
          <li><a href="http://www.access.gpo.gov/nara/cfr/waisidx_99/21cfr56_99.html">CFR 21 56</a>&nbsp; Institutional Review Boards</li>
          <li><a href="http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi?TITLE=21&amp;PART=310&amp;SECTION=305&amp;YEAR=1998&amp;TYPE=TEXT">CFR
 310.305</a>&nbsp; Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications </li>
          <li><a
            href="http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi?TITLE=21&amp;PART=314&amp;SECTION=70&amp;YEAR=1999&amp;TYPE=TEXT">CFR
 314.70</a>&nbsp; Supplements and other changes to an approved application</li>
          <li><a href="http://www.access.gpo.gov/nara/cfr/waisidx_00/21cfr320_00.html">CFR 320</a>&nbsp; Bioavailability and bioequivalence requirements</li>
            </ul>
            
            <table border="0" width="100%">
          <tr>
            <td width="100%" bgcolor="#D3FBFC"><span class="style7"><strong><em>Federal Food, Drug, and Cosmetic Act</em></strong></span></td>
          </tr>
            </table>
            <ul>
          <li><a href="http://www.fda.gov/cder/guidance/2853dft.htm">Draft Guidance forIndustry:&nbsp; Applications Covered by Section 505(b)(2)</a>. Optional format: <a
            href="http://www.fda.gov/cder/guidance/2853dft.pdf">PDF</a>. (Issued 10/1999)</li>
            
          <li><a href="http://thomas.loc.gov/cgi-bin/bdquery/z?d098:SN01538:@@@D&summ2=m&|TOM:/bss/d098query.html">Drug Price Competition and Patent Term Restoration Act of 1984</a></li>
          
          <li><a href="http://www.fda.gov/cder/guidance/2576fnl.pdf">Guidance for Industry: 180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food,  Drug, and Cosmetic Act</a> <img alt="PDF document" src="../graphics/pdf.gif" width="16" height="16"> (Issued 6/1998) </li>
          
          <li><a href="http://www.fda.gov/cder/guidance/3659fnl.htm">Court Decisions, ANDA Approvals,  and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act</a>. (Issued 3/2000) </li>
          
          <li><a href="http://www.fda.gov/cder/guidance/2891fnl.htm">Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act</a>. (Issued  9/1999). The FDA Modernization Act of 1997 permits certain   applications to obtain an additional six months of marketing exclusivity (pediatric exclusivity) if, in accordance with the requirements of the statute, the sponsor submits requested information relating to the use of the drug in the pediatric population.
            <ul>
              <li><a href="http://www.fda.gov/cder/ogd/pedtrac.htm">Useful pediatric exclusivity links</a>. &nbsp;This information is provided to assist generic drug applicants in determining whether a drug product might be or is subject to pediatric exclusivity.</li>
            </ul>
          </li>
            </ul>
            
            <table border="0" width="100%">
          <tr>
            <td width="100%" bgcolor="#D3FBFC"><span class="style7"><strong><em>Food and Drug Administration Modernization Act of 1997</em></strong></span></td>
          </tr>
            </table>
            
            <ul>
          <li><a href="http://www.fda.gov/cder/fdama/default.htm">FDA Modernization Act of 1997: CDER-Related Documents</a>.&nbsp; The Food and Drug Administration Modernization Act (FDAMA), enacted Nov. 21, 1997, amended the Federal Food, Drug, and Cosmetic Act relating  to the regulation of food, drugs, devices, and biological products.&nbsp; The Act focuses on streamlining regulatory procedures, setting new priorities, entering  into novel collaborative arrangements, and carrying out far-reaching managerial reforms within the Agency.&nbsp; Please see the <a
            href="http://www.fda.gov/opacom/backgrounders/modact.htm">FDAMA Backgrounder</a> for a summary of the most important provisions of the Act.&nbsp; <a href="http://www.fda.gov/opacom/7modact.html">Please see the FDA Modernization Act home page</a> for more information.</li>
            </ul>
          <p><small><a href="#top">Back to Top</a></small></p>
          
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><strong><a name="paragraph">Paragraph IV Drug Product Applications</a>:  Generic Drug Patent Challenge  Notifications</strong></h3></td>
        </tr>
          </table>
          
        <ul>
          <li><a href="ppiv.htm">Paragraph IV List</a>
            <p><a href="paragraph4.htm">CFR 314.94(a)(12)(i)(A)(4)</a><br>
              <em>...the applicant shall provide the patent number and certify, in its opinion and to the best of its knowledge, ...that the patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the abbreviated application is submitted. The applicant shall entitle such a certification &quot;Paragraph IV Certification&quot;. </em></p>
          </li>
            </ul>
            
          <p>Under the <a href="http://thomas.loc.gov/cgi-bin/bdquery/z?d098:SN01538:@@@D&summ2=m&|TOM:/bss/d098query.html">Drug Price Competition and Patent Term    Restoration Act</a>, or the Hatch-Waxman Act, a company can seek
                                approval from FDA to market a generic drug before the expiration of a patent relating to
                                the brand name drug upon which the generic is based.&nbsp; The first company to submit an
                                Abbreviated New Drug Application (ANDA) with the FDA has the exclusive right to market the
                                generic drug for 180 days.</p>
                                
          <p>To begin the FDA approval process, the generic
                                applicant must: 1) certify in its ANDA that the patent in question is invalid or is not
                                infringed by the generic product (known as &quot;paragraph IV certification&quot;); and 2)
                                notify the patent holder of the submission of the ANDA.&nbsp; If the patent holder files
                                an infringement suit against the generic applicant within 45 days of the ANDA
                                notification, FDA approval to market the generic drug is automatically postponed for 30
                                months, unless, before that time, the patent expires or is judged to be invalid or not
                                infringed.&nbsp; This 30-month postponement allows the patent holder time to assert its
                                patent rights in court before a generic competitor is permitted to enter.</p>
                                
          <p><small><a href="#top" class="style7">Back to Top</a></small></p>
          
          <table border="0" width="101%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3 class="style7"><a name="Petition"><strong>Generic Drug Petition Tracking</strong></a></h3></td>
        </tr>
          </table>
          
          <ul>
        <li>
          <p align="left"><a href="suitabil.htm">Suitability Tracking Reports</a></p>
        </li>
          </ul>
          <p>These petitions are submitted to FDA by drug companies seeking permission
                                to file an abbreviated new drug application for a change from a listed drug in dosage
                                form, strength, route of administration, or active ingredient in a combination product.
                                &nbsp; If FDA determines that the drug is suitable for a generic product, the petition is
                                approved, if it is not suitable, the petition is denied.</p>
                                
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><strong><a name="Org">Organization and Contact Information</a></strong></h3></td>
        </tr>
          </table>
       
          <ul>
          <li><a href="review_teams.htm">Chemistry and Bioequivalence Review Teams for Drug Therapeutic Categories</a></li>  
          <li><a href="ogddir.htm">Office of Generic Drugs Telephone Directory</a></li>
          </ul>
          
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><a name="FOI"><strong>Freedom of Information</strong></a></h3></td>
        </tr>
          </table>
          
          <ul>
        <li>
          <p><a href="http://www.fda.gov/cder/foi/index.htm">The Freedom of
                                    Information web page</a> provides access to information from advisory committees; clinical
                                    investigators; the Division of Drug Marketing, Advertising and Communications
                                    correspondence; drug approval packages; and warning letters.</p>
        </li>
          </ul>
          
          <table border="0" width="100%">
        <tr>
          <td width="100%" bgcolor="#CAEEFD"><h3><a name="Contact">How to Contact Us</a></h3></td>
        </tr>
          </table>
          <p><strong><a name="mailaddress" id="mailaddress"></a>OGD Mailing Address:</strong></p>
          <p>Office of Generic Drugs<br>
            Center for Drug Evaluation and Research<br>
            OGD Document Room<br>
            7500 Standish Place<br>
            Rockville, MD 20855</p>
          <p>We  highly recommend that firms consider submitting documents in electronic format. The OGD document room has limited space and resources to maintain paper documents.</p>
          <hr>
          <p>We ask you to take time to communicate with CDER about this website.  What information is and isn't useful to you?&nbsp; Are there any additional items or categories of information you would like us to add?&nbsp;  Please e-mail Timothy W. Ames, <a href="mailto:timothy.ames@fda.hhs.gov">timothy.ames@fda.hhs.gov</a> with feedback about this site.</p>
          <p><img alt="PDF symbol" border="0" src="../graphics/pdf.gif" width="16" height="16"> PDF requires the free <a href="http://www.fda.gov/cder/pdf.htm">Adobe Acrobat Reader</a></p>        </td>
      </tr>
    </tbody>
  </table>
                   
                  
                    <p align="center"> <img border="0" src="http://www.fda.gov/cder/templates/graphics/totop_arrow.gif" width="12" height="19">  <a href="#top">Back to Top</a>&nbsp;&nbsp;&nbsp;&nbsp; <img border="0" src="http://www.fda.gov/cder/templates/graphics/back_arrow.gif" width="12" height="14"> <a href="../office.htm">Back to Offices and  Divisions </a> </p>
               </td>
              </tr>
              <tr>
                <td width=6><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=153><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=515><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=8><img height=4 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
              </tr>
              <tr>
                <td width=6><img height=2 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width=153><img height=2 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
                <td width="100%"><img height=2 src="../templates/Graphics/redline.gif" 
            width="100%"></td>
                <td width=8><img height=2 src="../templates/Graphics/dot_clear.gif" 
            width="100%"></td>
              </tr>
              <tr>
                <td width=6><img src="../templates/Graphics/dot_clear.gif" width="1" height="1"></td>
                <td width=153><div align=left><font 
            color=#000066 class="header">Updated: December 18, 2008 </font> </div></td>
                <td width=515><div class=contentItem> </div>
                  <div class=contentItem> <img height=2 
            src="../templates/Graphics/dot_clear.gif" width="100%"></div></td>
                <td width=8><img src="../templates/Graphics/dot_clear.gif" width="1" height="1"></td>
              </tr>
            </tbody>
          </table>
          <table cellspacing=2 cellpadding=0 width="100%" bgcolor=#ffffff 
        border=0>
            <tbody>
              <tr>
                <td align="center" width=10></td>
                <td valign="middle" align="center" colspan=5><img height=10 alt=" " 
            src="../templates/Graphics/dot_clear.gif" width="97%" border=0></td>
                <td align="center" width=10></td>
              </tr>
              <tr>
                <td valign="middle" align="center" colspan=7 height=10><img height=1 
            alt="horizonal rule" src="../templates/Graphics/blkpixel.gif" 
            width="100%" border=0></td>
              </tr>
              <tr>
                <td align="center" width=10></td>
                <td colspan=5><p class=footer><a href="http://www.fda.gov/cder"><span 
            class=redcder>CDER</span> Home Page</a> | <a href="http://www.fda.gov/cder/site/default.htm">CDER Site Info</a> | <a 
            href="http://www.fda.gov/cder/comment.htm">Contact CDER </a>| <a 
                  href="http://www.fda.gov/cder/whatsnew.htm">What's New @ CDER</a><br>
                    <a href="http://www.fda.gov/default.htm">FDA Home Page</a> | <a href="http://www.fda.gov/search.html">Search FDA Site</a> | <a href="http://www.fda.gov/opacom/hpchoice.html">FDA A-Z Index</a> | <a href="http://www.fda.gov/comments.html">Contact FDA</a> | <a href="http://www.fda.gov/privacy.html">Privacy</a> | <a href="http://www.hhs.gov/Accessibility.html">Accessibility</a> | <a href="http://www.hhs.gov/">HHS Home Page</a></p>
                  <p class=footer>FDA/Center for Drug Evaluation and 
                    Research<br>
                </p></td>
                <td align="center" width=10></td>
              </tr>
              <tr>
                <td align="center" width=10></td>
                <td valign="middle" align="center" colspan=5><img height=10 alt=" " 
            src="../templates/Graphics/dot_clear.gif" width="97%" border=0></td>
                <td align="center" 
width=10></td>
              </tr>
            </tbody>
          </table>
        </div></td>
    </tr>
  </tbody>
</table>

</body>
</html>
